Pfizer Inc. (NYSE:PFE) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Pfizer Inc. (NYSE:PFE) have been given a consensus rating of “Moderate Buy” by the fifteen research firms that are presently covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $34.54.

Several research firms have recently issued reports on PFE. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. UBS Group upped their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. StockNews.com downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, September 16th. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th.

Pfizer Price Performance

Shares of PFE opened at $28.67 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The firm has a market cap of $162.46 billion, a PE ratio of -477.83, a PEG ratio of 1.27 and a beta of 0.68. Pfizer has a twelve month low of $25.20 and a twelve month high of $34.11. The firm’s 50 day moving average price is $29.28 and its 200 day moving average price is $28.31.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.67 EPS. As a group, research analysts expect that Pfizer will post 2.66 EPS for the current fiscal year.

Hedge Funds Weigh In On Pfizer

Several large investors have recently added to or reduced their stakes in the company. Olistico Wealth LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer in the 2nd quarter valued at $29,000. Quarry LP acquired a new position in shares of Pfizer in the 2nd quarter valued at $31,000. Creekmur Asset Management LLC bought a new position in shares of Pfizer during the 4th quarter worth about $32,000. Finally, Trivant Custom Portfolio Group LLC boosted its position in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.